Davide Stolfo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4568501/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Prognostic significance of longitudinal strain in dilated cardiomyopathy with recovered ejection fraction. Heart, 2022, 108, 710-716.	2.9	5
2	Heart failure with mid-range or mildly reduced ejection fraction. Nature Reviews Cardiology, 2022, 19, 100-116.	13.7	156
3	Inferior Vena Cava Edge Tracking Echocardiography: A Promising Tool with Applications in Multiple Clinical Settings. Diagnostics, 2022, 12, 427.	2.6	5
4	Echocardiographic Biventricular Coupling Index to Predict Precapillary Pulmonary Hypertension. Journal of the American Society of Echocardiography, 2022, 35, 715-726.	2.8	6
5	Association of Premature Ventricular Contraction Burden on Serial Holter Monitoring With Arrhythmic Risk in Patients With Arrhythmogenic Right Ventricular Cardiomyopathy. JAMA Cardiology, 2022, 7, 378.	6.1	8
6	The right ventricular involvement in dilated cardiomyopathy: prevalence and prognostic implications of the often-neglected child. Heart Failure Reviews, 2022, 27, 1795-1805.	3.9	5
7	Effect of prehospital treatment in STEMI patients undergoing primary PCI. Catheterization and Cardiovascular Interventions, 2022, 99, 1500-1508.	1.7	9
8	The paradox of pulmonary arterial hypertension in Italy in the COVID-19 era: is risk of disease progression around the corner?. European Respiratory Journal, 2022, 60, 2102276.	6.7	8
9	Global Longitudinal Strain is Incremental to Left Ventricular Ejection Fraction for the Prediction of Outcome in Optimally Treated Dilated Cardiomyopathy Patients. Journal of the American Heart Association, 2022, 11, e024505.	3.7	21
10	Use of evidenceâ€based therapy in heart failure with reduced ejection fraction across age strata. European Journal of Heart Failure, 2022, 24, 1047-1062.	7.1	37
11	Transient versus persistent improved ejection fraction in nonâ€ischaemic dilated cardiomyopathy. European Journal of Heart Failure, 2022, 24, 1171-1179.	7.1	16
12	Importance of genotype for risk stratification in arrhythmogenic right ventricular cardiomyopathy using the 2019 ARVC risk calculator. European Heart Journal, 2022, 43, 3053-3067.	2.2	41
13	Evidence-based Therapy in Older Patients with Heart Failure with Reduced Ejection Fraction. Cardiac Failure Review, 2022, 8, e16.	3.0	6
14	Reply to the Letter to the Editor entitled "The importance of anti-fibrotic drugs as first-line therapy in patients with arrhythmogenic right ventricular dysplasia― International Journal of Cardiology, 2022, , .	1.7	0
15	From mid-range to mildly reduced ejection fraction heart failure: A call to treat. European Journal of Internal Medicine, 2022, 103, 29-35.	2.2	5
16	Lower socioeconomic status predicts higher mortality and morbidity in patients with heart failure. Heart, 2021, 107, 229-236.	2.9	26
17	Prognostic relevance of pericardial effusion in STEMI patients treated by primary percutaneous coronary intervention: a 10-year single-centre experience. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 71-80.	1.0	4
18	Use of <scp>sodium–glucose</scp> coâ€transporter 2 inhibitors in patients with heart failure and type 2 diabetes mellitus: data from the Swedish Heart Failure Registry. European Journal of Heart Failure, 2021, 23, 1012-1022.	7.1	33

#	Article	IF	CITATIONS
19	Impaired Right Ventricular Longitudinal Strain Without Pulmonary Hypertension in Patients Who Have Recovered From COVID-19. Circulation: Cardiovascular Imaging, 2021, 14, e012166.	2.6	21
20	Association between heart failure and cancer: is gender the answer?. European Journal of Heart Failure, 2021, 23, 1722-1724.	7.1	2
21	Antiarrhythmic therapy and risk of cumulative ventricular arrhythmias in arrhythmogenic right ventricle cardiomyopathy. International Journal of Cardiology, 2021, 334, 58-64.	1.7	13
22	Prevalence and evolution of right ventricular dysfunction among different genetic backgrounds in dilated cardiomyopathy. Canadian Journal of Cardiology, 2021, 37, 1743-1750.	1.7	6
23	Impact on clinical outcomes of right ventricular response to percutaneous correction of secondary mitral regurgitation. European Journal of Heart Failure, 2021, 23, 1765-1774.	7.1	13
24	Phenotypic Expression, Natural History, and Risk Stratification of Cardiomyopathy Caused by Filamin C Truncating Variants. Circulation, 2021, 144, 1600-1611.	1.6	43
25	Assessment of Phasic Changes of Vascular Size by Automated Edge Tracking-State of the Art and Clinical Perspectives. Frontiers in Cardiovascular Medicine, 2021, 8, 775635.	2.4	8
26	297 Echocardiographic biventricular coupling index to predict pre-capillary pulmonary hypertension. European Heart Journal Supplements, 2021, 23, .	0.1	0
27	415 Correlation between tissue abnormalities and myocardial deformation indices in arrhythmogenic cardiomyopathy: a pilot study. European Heart Journal Supplements, 2021, 23, .	0.1	0
28	350 Effect of pre-hospital treatment for STEMI patients undergoing primary PCI. European Heart Journal Supplements, 2021, 23, .	0.1	0
29	Association between betaâ€blocker use and mortality/morbidity in older patients with heart failure with reduced ejection fraction. A propensity scoreâ€matched analysis from the Swedish Heart Failure Registry. European Journal of Heart Failure, 2020, 22, 103-112.	7.1	27
30	Global Right Heart Assessment with Speckle-Tracking Imaging Improves the Risk Prediction of a Validated Scoring System in Pulmonary Arterial Hypertension. Journal of the American Society of Echocardiography, 2020, 33, 1334-1344.e2.	2.8	14
31	Modifications of medical treatment and outcome after percutaneous correction of secondary mitral regurgitation. ESC Heart Failure, 2020, 7, 1753-1763.	3.1	8
32	Accuracy of right atrial pressure estimation using a multi-parameter approach derived from inferior vena cava semi-automated edge-tracking echocardiography: a pilot study in patients with cardiovascular disorders. International Journal of Cardiovascular Imaging, 2020, 36, 1213-1225.	1.5	14
33	Sexâ€related differences in therapeutic response to mineralocorticoid receptor antagonists in heart failure: summarizing trial evidence. European Journal of Heart Failure, 2020, 22, 845-847.	7.1	0
34	Risk of sudden cardiac death in New York Heart Association class I patients with dilated cardiomyopathy: A competing risk analysis. International Journal of Cardiology, 2020, 307, 75-81.	1.7	6
35	Contemporary survival trends and aetiological characterization in nonâ€ischaemic dilated cardiomyopathy. European Journal of Heart Failure, 2020, 22, 1111-1121.	7.1	54

Prognostic Stratification and Importance of Follow-Up. , 2019, , 187-198.

0

#	Article	IF	CITATIONS
37	Dilated Cardiomyopathy With Midâ€Range Ejection Fraction at Diagnosis: Characterization and Natural History. Journal of the American Heart Association, 2019, 8, e010705.	3.7	9
38	Association Between Use of Primary-Prevention Implantable Cardioverter-Defibrillators and Mortality in Patients With Heart Failure. Circulation, 2019, 140, 1530-1539.	1.6	78
39	Genetic Risk of Arrhythmic Phenotypes in Patients With Dilated Cardiomyopathy. Journal of the American College of Cardiology, 2019, 74, 1480-1490.	2.8	167
40	Prognostic Value of Global Longitudinal Strain-Based Left Ventricular Contractile Reserve in Candidates for Percutaneous Correction of Functional Mitral Regurgitation: Implications for Patient Selection. Journal of the American Society of Echocardiography, 2019, 32, 1436-1443.	2.8	14
41	Sex-Based Differences in HeartÂFailure Across the Ejection Fraction Spectrum. JACC: Heart Failure, 2019, 7, 505-515.	4.1	114
42	Regional Variation in <i>RBM20</i> Causes a Highly Penetrant Arrhythmogenic Cardiomyopathy. Circulation: Heart Failure, 2019, 12, e005371.	3.9	96
43	Treatment of Functional Mitral Regurgitation in Heart Failure. Current Cardiology Reports, 2019, 21, 139.	2.9	1
44	Arrhythmic risk stratification in patients with dilated cardiomyopathy and intermediate left ventricular dysfunction. Journal of Cardiovascular Medicine, 2019, 20, 343-350.	1.5	13
45	ECG in dilated cardiomyopathy: specific findings and long-term prognostic significance. Journal of Cardiovascular Medicine, 2019, 20, 450-458.	1.5	27
46	Chronic thromboembolic pulmonary hypertension (CTEPH): what do we know about it? A comprehensive review of the literature. Journal of Cardiovascular Medicine, 2019, 20, 159-168.	1.5	17
47	Left bundle branch block in dilated cardiomyopathy with intermediate left ventricular dysfunction: Clinical phenotyping and outcome correlates. International Journal of Cardiology, 2019, 278, 180-185.	1.7	4
48	Use of Renin–Angiotensin–Aldosterone System Inhibitors in Older Patients with Heart Failure and Reduced Ejection Fraction. Cardiac Failure Review, 2019, 5, 70-73.	3.0	7
49	Clinical Presentation, Spectrum of Disease, and Natural History. , 2019, , 71-82.		1
50	Evolving concepts in dilated cardiomyopathy. European Journal of Heart Failure, 2018, 20, 228-239.	7.1	233
51	Predicting device failure after percutaneous repair of functional mitral regurgitation in advanced heart failure: Implications for patient selection. International Journal of Cardiology, 2018, 257, 182-187.	1.7	26
52	Cardiac fluid dynamics meets deformation imaging. Cardiovascular Ultrasound, 2018, 16, 4.	1.6	7
53	Arrhythmic Risk Stratification in Patients With Idiopathic Dilated Cardiomyopathy. American Journal of Cardiology, 2018, 121, 1601-1609.	1.6	26
54	Left ventricular reverse remodeling prediction in non-ischemic cardiomyopathy: present and perspectives. Expert Review of Cardiovascular Therapy, 2018, 16, 771-773.	1.5	4

#	Article	IF	CITATIONS
55	Usefulness of Addition of Magnetic Resonance Imaging to Echocardiographic Imaging to Predict Left Ventricular Reverse Remodeling in Patients With Nonischemic Cardiomyopathy. American Journal of Cardiology, 2018, 122, 490-497.	1.6	13
56	Association between mutation status and left ventricular reverse remodelling in dilated cardiomyopathy. Heart, 2017, 103, 1704-1710.	2.9	64
57	Insights into mildly dilated cardiomyopathy: temporal evolution and longâ€ŧerm prognosis. European Journal of Heart Failure, 2017, 19, 531-539.	7.1	32
58	Comparison of Patient Characteristics and Course of Hypertensive Hypokinetic Cardiomyopathy Versus Idiopathic Dilated Cardiomyopathy. American Journal of Cardiology, 2017, 119, 483-489.	1.6	14
59	Early right ventricular response to cardiac resynchronization therapy: impact on clinical outcomes. European Journal of Heart Failure, 2016, 18, 205-213.	7.1	13
60	Natural History of Dilated Cardiomyopathy in Children. Journal of the American Heart Association, 2016, 5, .	3.7	39
61	ST-elevation myocardial infarction with reduced left ventricular ejection fraction: Insights into persisting left ventricular dysfunction. A pPCI-registry analysis. International Journal of Cardiology, 2016, 215, 340-345.	1.7	15
62	Early Arrhythmic Events in IdiopathicÂDilated Cardiomyopathy. JACC: Clinical Electrophysiology, 2016, 2, 535-543.	3.2	24
63	Prognostic value of cardiopulmonary exercise testing in Idiopathic Dilated Cardiomyopathy. International Journal of Cardiology, 2016, 223, 596-603.	1.7	30
64	Characterization and Long-Term Prognosis of Postmyocarditic Dilated Cardiomyopathy Compared With Idiopathic Dilated Cardiomyopathy. American Journal of Cardiology, 2016, 118, 895-900.	1.6	10
65	Truncating FLNC Mutations Are Associated With High-Risk Dilated and Arrhythmogenic Cardiomyopathies. Journal of the American College of Cardiology, 2016, 68, 2440-2451.	2.8	340
66	An interesting case of left-to-right shunt. Journal of Cardiovascular Medicine, 2016, 17, e122-e123.	1.5	0
67	The Prognostic Impact of the Evolution ofÂRV Function in IdiopathicÂDCM. JACC: Cardiovascular Imaging, 2016, 9, 1034-1042.	5.3	92
68	Acute Hemodynamic Response to Cardiac Resynchronization in Dilated Cardiomyopathy: Effect on Late Mitral Regurgitation. PACE - Pacing and Clinical Electrophysiology, 2015, 38, 1287-1296.	1.2	14
69	Persistent Recovery of Normal Left Ventricular Function and Dimension in Idiopathic Dilated Cardiomyopathy During Longâ€Term Followâ€up: Does Real Healing Exist?. Journal of the American Heart Association, 2015, 4, e001504.	3.7	73
70	Early Improvement of Functional Mitral Regurgitation in Patients With Idiopathic Dilated Cardiomyopathy. American Journal of Cardiology, 2015, 115, 1137-1143.	1.6	52
71	Calcific degeneration and rupture of the aortic valve and ascending aorta: from cardiac auscultation to multimodality imaging. Journal of Geriatric Cardiology, 2015, 12, 580-3.	0.2	1
72	Longâ€ŧerm prognostic impact of therapeutic strategies in patients with idiopathic dilated cardiomyopathy: changing mortality over the last 30 years. European Journal of Heart Failure, 2014, 16, 317-324.	7.1	177

#	Article	IF	CITATION
73	Dilated Cardiomyopathy: Usefulness of Imaging in Prognostic Stratification and Choice of Treatment. , 2014, , 75-81.		0
74	Other Cardiomyopathies: Clinical Assessment and Imaging in Diagnosis and Patient Management. , 2014, , 249-280.		0
75	Dilated Cardiomyopathy: Clinical Assessment and Differential Diagnosis. , 2014, , 35-44.		0
76	Obesity and high waist circumference are associated with low circulating pentraxin-3 in acute coronary syndrome. Cardiovascular Diabetology, 2013, 12, 167.	6.8	23
77	Early repolarization in arrhythmogenic left ventricular cardiomyopathy: insights from cardiac magnetic resonance imaging. International Journal of Cardiology, 2012, 159, 66-68.	1.7	1
78	Deleterious impact of mild anemia on survival of young adult patients (age 45 ± 14 years) with idiopathic dilated cardiomyopathy: Data from the Trieste Cardiomyopathies Registry. Heart and Lung: Journal of Acute and Critical Care, 2011, 40, 454-461.	1.6	7
79	Natural history of dilated cardiomyopathy: from asymptomatic left ventricular dysfunction to heart failure – a subgroup analysis from the Trieste Cardiomyopathy Registry. Journal of Cardiovascular Medicine. 2009. 10. 699-705.	1.5	41